Spotlighting Shifting Treatment Trends in Acute Lymphoblastic Leukemia

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss evolving treatment trends in acute lymphoblastic leukemia.

EP. 1: Current First-Line Treatment Considerations in Acute Lymphoblastic Leukemia

August 25th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.

EP. 2: Defining the Role of Blinatumomab in Acute Lymphoblastic Leukemia

August 25th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab in acute lymphoblastic leukemia management.

EP. 3: Adding Blinatumomab to the CALGB 10403 Regimen in B-Cell Precursor ALL in MRD-Negative Remission

September 2nd 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.

EP. 4: Blinatumomab Consolidation in Younger Adult BCR:ABL1–Negative B-ALL

September 2nd 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab consolidation in BCR:ABL1–negative B-ALL.

EP. 5: Early Data for Subcutaneous Blinatumomab in R/R ALL

September 8th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss data for subcutaneous in relapsed/refractory acute lymphoblastic leukemia.

EP. 6: Highlighting Key ALL Updates and Data From EHA 2025

September 8th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.